17 Dec 2015
Trading ahead of expectations
Cyprotex has had a very impressive performance in its 2015 financial year with the group flagging that it has had a very strong Q4. The Board anticipates that its full year EBITDA will exceed market expectations. We upgrade our 2015 forecasts for the third time since the trading update in June. We believe Cyprotex has the ability to continue to expand its service offering, attract new customers and expand into new end markets.